Table 2 Mantel-Haenszel odds ratios of different adverse events (Alogliptin 25 mg vs control; Alogliptin 12.5 mg vs control), 2012

Adverse events

Over all odds Ratios (95% CI)

I²

Number of included studies

Any skin or subcutaneous adverse events

0.91 [0.60, 1.40]

0%

3[13, 20, 21]

Headache

1.07 [0.64, 1.78]

0%

4[13, 18–20]

Arthralgia

0.79 [0.37, 1.72]

24%

3[13, 18, 19]

Nasopharyngitis

1.34 [0.92, 1.95]

0%

6[13, 18–21, 24]

Diarrhoea

1.36 [0.34, 5.49]

74%

4[13, 18, 19, 21]

Peripheral oedema

0.98 [0.60, 1.61]

0%

4[13, 18, 20, 24]

Gastrointestinal adverse events

1.04 [0.74, 1.46]

0%

4[13, 19–21]

Urinary tract infection

0.98 [0.54, 1.77]

45%

4[13, 18, 19, 21]

 Upper respiratory tract infection

0.77 [0.32, 1.86]

67%

4[18–21]

Infection or infestation

0.87 [0.67, 1.13]

0%

4[13, 19–21]

Bronchitis

0.72 [0.24, 2.14]

58%

4[18–21]

Influenza

0.83 [0.49, 1.38]

0%

3[18, 20, 21]

Hypoglycaemia

0.97 [0.23, 4.01]

75%

3[18, 19, 21]

Hypertension

1.09 [0.57, 2.08]

22%

3[18, 19, 21]

Alogliptin 12.5 mg treated vs control

Any skin or subcutaneous adverse events

0.86 [0.56, 1.33]

0%

3[13, 20, 21]

Headache

1.23 [0.59, 2.55]

0%

3[13, 19, 20]

Arthralgia

1.08 [0.14, 8.57]

79%

2[13, 19]

Nasopharyngitis

0.86 [0.50, 1.46]

0%

5[13, 19–21, 24]

Diarrhoea

1.15 [0.19, 6.80]

50%

3[13, 19, 21]

Peripheral oedema

0.80 [0.37, 1.72]

0%

3[13, 19, 24]

Gastrointestinal adverse events

0.88 [0.62, 1.24]

0%

4[13, 19–21]

Urinary tract infection

1.17 [0.62, 2.23]

0%

3[13, 19, 21]

 Upper respiratory tract infection

0.66 [0.34, 1.27]

5%

3[19–21]

Infectionn or infestation

1.01 [0.78, 1.31]

0%

4[13, 19–21]

Bronchitis

0.72 [0.24, 2.16]

38%

3[19–21]

Influenza

0.42 [0.15, 1.17]

0%

2[20, 21]

Hypoglycaemia

0.87 [0.20, 3.69]

59%

2[19, 21]

Hypertension

0.76 [0.17, 3.38]

52%

2[19, 21]